Johnson & Johnson Drug Receives Positive Data in Trials (JNJ)
According to data being presented at a medical meeting in Europe, Johnson & Johnson’s (JNJ) new drug to combat psoriatic arthritis, Stelara, has produced positive results in recent testing and trials.
Through 52 weeks of treatment the drug has produced significant improvements in psoriatic arthritis symptoms.
Psoriatic arthritis is a chronic inflammatory condition in which joint pain is caused by the immune system attacking healthy tissues. Many patients are treated with anti-TNF drugs such as AbbVie’s (ABBV) Humira and Johnson & Johnson’s own Remicade.
Johnson & Johnson shares were up 31 cents, or +0.37%, during pre-market trading on Wednesday. The stock is up +20.81% year-to-date.
The Bottom Line
Shares of Johnson & Johnson (JNJ) have a dividend yield of 3.12% based on last night’s closing price of $84.69 and the company’s annualized dividend payout of $2.64 per share.
Johnson & Johnson (JNJ) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars.
Get FREE Dividend Tips, Updates & MoreWe respect your privacy
- Powerful dividend insights sent every weekday morning
- Gain instant access to actionable investing tips
- Strategically grow your portfolio’s profitability